Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Herceptin
|
| gptkbp:activities |
inhibits HE R2 signaling
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:1998
gptkb:FDA |
| gptkbp:associated_with |
patient education
clinical trials improved quality of life supportive care healthcare costs patient adherence treatment guidelines improved survival rates long-term remission reduced recurrence rates |
| gptkbp:can_be_used_with |
chemotherapy
|
| gptkbp:class |
targeted therapy
|
| gptkbp:clinical_trial |
Phase III
metastatic breast cancer early-stage breast cancer |
| gptkbp:combatants |
high
|
| gptkbp:contraindication |
pregnancy
severe heart failure hypersensitivity to trastuzumab |
| gptkbp:developed_by |
gptkb:Genentech
|
| gptkbp:financial_performance |
room temperature
|
| gptkbp:formulation |
lyophilized powder
|
| https://www.w3.org/2000/01/rdf-schema#label |
trastuzumab-pkrb
|
| gptkbp:indication |
HE R2-positive breast cancer
|
| gptkbp:is_monitored_by |
cardiac function
infusion reactions |
| gptkbp:is_used_for |
breast cancer treatment
|
| gptkbp:is_vulnerable_to |
low
|
| gptkbp:lifespan |
approximately 5-8 days
|
| gptkbp:manager |
subcutaneous
|
| gptkbp:marketed_as |
gptkb:Herceptin
|
| gptkbp:pharmacokinetics |
HE R2 receptor blockade
dose-dependent |
| gptkbp:population |
adult men
adult women |
| gptkbp:research_focus |
biomarker identification
combination therapies resistance mechanisms new formulations pediatric applications |
| gptkbp:rounds |
hepatic metabolism
|
| gptkbp:side_effect |
nausea
diarrhea infusion reactions cardiotoxicity |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
HE R2
|
| gptkbp:used_in |
adjuvant therapy
neoadjuvant therapy |